“As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with several prominent centers across the U.S. now enrolling patients, we are pleased to have secured a direct investment of US$11.4 million to strengthen our balance sheet and accelerate the development of our novel heart failure drug, CRD-38, based on the recently reported findings from our ARCHER trial,” said David Elsley, President and CEO of Cardiol Therapeutics. #Investors #Shareholders
https://x.com/CardiolRx/status/1980597498398830645